NCT06315166

Study on Using Radiofrequency to Treat Moderate to Severe Acne

Clinical Evaluation of Fractional Radiofrequency for the Treatment of Moderate to Severe Acne Vulgaris

• Status: Active Not Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Pollogen · Industry
• Sex: All
• Age: 18 Years – 25 Years
• Healthy volunteers: Not accepted

Summary

Evaluation of the safety and efficacy of fractional radiofrequency for the treatment of moderate to severe acne vulgaris.

Detailed description

This is an interventional, multicenter, open (self-controlled) trial to evaluate the safety and efficacy of fractional radiofrequency for the treatment of moderate to severe acne vulgaris. The study will evaluate up to 30 male or female participants requesting treatment for the reduction of moderate to severe acne vulgaris. The study will involve three treatments of fractional radiofrequency. Treatments will be randomized with combination antibiotic/ fractional radiofrequency therapy. The subject will act as their own control, where one side of the face (buccal area) will be treated, and the other will not be and will act as the control.

Conditions

• Moderate to Severe Acne Vulgaris

Interventions

Type	Name	Description
DEVICE	triLift/Legend Pro+ Fractional RF System	The triLift/Legend Pro+ Fractional investigational device is intended for the treatment of acne vulgaris when using Fractional RF energy.

Timeline

• Start date: 2024-05-23
• Primary completion: 2026-12-01
• Completion: 2027-12-01
• First posted: 2024-03-18
• Last updated: 2026-02-19

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated device study